Track market-moving stories before they get noisy

Enterprise Products Partners is positioned to benefit from surging AI data center power demand as buildouts accelerate in the years ahead. EPD's stable and growing distribution, with a 1.8X coverage ratio and record $4.08 TTM adjusted cash flow per unit, underpins my 'Strong Buy' rating. Major acquisitions and robust EBITDA growth—over 50% in five years—support EPD's long-term cash flow expansion amid growing AI-driven energy demand.

Enterprise Products Partners (EPD) closed the most recent trading day at $37.92, moving +1.53% from the previous trading session.

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the commercial availability of Epioxa™ HD / Epioxa™ (“Epioxa”), a groundbreaking advancement in corneal cross-linking for the treatment of keratoconus, a rare, sight-threatening corneal disease that is currently far too often undiagnosed and untreated.

Glaukos Corporation (NYSE: GKOS - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the sixteen brokerages that are currently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation, twelve have issued a buy recommendation and one has

Glaukos Corporation (NYSE: GKOS - Get Free Report) CFO Alex Thurman sold 2,511 shares of the firm's stock in a transaction that occurred on Wednesday, March 25th. The shares were sold at an average price of $106.46, for a total value of $267,321.06. Following the completion of the sale, the chief financial officer directly owned 41,967

Glaukos (NYSE: GKOS - Get Free Report) and Anteris Technologies Global (NASDAQ: AVR - Get Free Report) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, risk, analyst recommendations, dividends, profitability, valuation and earnings. Volatility and Risk Glaukos has a beta of

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today that its technologies will be featured in various scientific programming at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, being held April 10-13, 2026 in Washington, D.C. Glaukos will be exhibiting onsite at booth #407.

-

New J-code for Epioxa™, J2789, set to become effective July 1, 2026

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, announced today the U.S. Centers for Medicare and Medicaid Services (CMS) has assigned a unique, permanent Healthcare Common Procedure Coding System (HCPCS) J-code for Epioxa™ HD / Epioxa™ (“Epioxa”) for the treatment of keratoconus, a rare, sight-threatening disease that is currently far too often undiagnosed and untreated.

The new J-code for Epioxa, J2789, is set to become effective July 1, 2026. It is expected to streamline the reporting and payment of Epioxa by U.S. payers over time, and has been published here on the CMS website.

“The assignment of a product-specific J-code for Epioxa represents an important milestone, supporting our market access initiatives to increase access and expand coverage for patients suffering from keratoconus,” said Thomas Burns, Glaukos chairman and chief executive officer. “Once effective, this new J-code is expected to enable more streamlined and consistent coverage and payment for Epioxa over time, strengthening the foundation for our commercial launch and enabling broader patient access.”

J-codes are reported by U.S. healthcare providers and used by U.S. government and commercial payers to streamline the billing and reimbursement process for pharmaceuticals, such as Epioxa, administered by a healthcare professional.

Epioxa represents a transformative innovation in keratoconus care, offering an incision-free alternative to traditional corneal cross-linking procedures as it does not require the removal of the corneal epithelium, the outermost layer of the front of the eye. This novel, oxygen-enriched topical therapeutic, bioactivated by UV light, is designed to eliminate the pain associated with removal of the epithelium, streamline the procedure, and minimize recovery, all while delivering clinically meaningful outcomes and exceptional value to patients, providers, and the healthcare system.

About Glaukos

Glaukos (www.glaukos.com) is an ophthalmic pharmaceutical and medical technology company focused on developing and commercializing novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. Glaukos first developed Micro-Invasive Glaucoma Surgery (MIGS) as an alternative to the traditional glaucoma treatment paradigm, launching its first MIGS device commercially in 2012. In 2024, Glaukos commenced commercial launch activities for iDose® TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical designed to deliver 24/7 glaucoma drug therapy inside the eye for extended periods of time. Glaukos also markets the only FDA-approved corneal cross-linking therapy utilizing a proprietary bio-activated pharmaceutical for the treatment of keratoconus, a rare corneal disorder. Glaukos continues to successfully develop and advance a robust pipeline of novel, dropless platform technologies designed to meaningfully advance the standard of care and improve outcomes for patients suffering from chronic eye diseases.

About Epioxa HD / Epioxa

Indication: EPIOXA™ HD (riboflavin 5’-phosphate ophthalmic solution) 0.239% and EPIOXA™ (riboflavin 5’-phosphate ophthalmic solution) 0.177% are photoenhancers indicated for use in epithelium-on corneal collagen cross-linking for the treatment of keratoconus in adults and pediatric patients aged 13 years and older, in conjunction with the O2n™ System and the Boost Goggles®.

Dosage and Administration: EPIOXA HD and EPIOXA are for topical ophthalmic use. NOT for injection or intraocular use. EPIOXA HD and EPIOXA are supplied in single-dose syringes. Discard opened syringes after use. EPIOXA HD and EPIOXA are for use with the O2n System and Boost Goggles only. Refer to the O2n System Operator’s Manual and Boost Goggles User Guide for device instructions.

Contraindications: EPIOXA HD and EPIOXA are contraindicated in patients with known hypersensitivity to benzalkonium chloride or any ingredients in EPIOXA HD and EPIOXA. Epithelium-on corneal collagen cross-linking is contraindicated in aphakic and pseudophakic patients without a UV-blocking intraocular lens.

Warnings and Precautions: Corneal collagen cross-linking should be used with caution in patients with a history of herpetic keratitis due to the potential for reactivation of herpes keratitis.

Adverse Reactions: The most common adverse reaction was conjunctival hyperaemia (31%). Other adverse reactions, occurring in 5% to 25% of eyes included: corneal opacity (haze), photophobia, punctate keratitis, eye pain, eye irritation, increased lacrimation, corneal epithelium defect, eyelid oedema, corneal striae, visual acuity reduced, dry eye, and anterior chamber flare.

For more information, visit www.glaukos.com.

Forward-Looking Statements

All statements other than statements of historical facts included in this press release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements. Although we believe that we have a reasonable basis for forward-looking statements contained herein, we caution you that they are based on current expectations about future events affecting us and are subject to risks, uncertainties and factors relating to our operations and business environment, all of which are difficult to predict and many of which are beyond our control, that may cause our actual results to differ materially from those expressed or implied by forward-looking statements in this press release. These potential risks and uncertainties include, without limitation, the timing and extent to which we obtain regulatory approval for investigational products, our ability to successfully commercialize such products, the ability to obtain and maintain adequate financial coverage and reimbursement for our products, the continued efficacy and safety profile of our products, and the extent to which this new J-code will enable more streamlined and consistent coverage and payment for Epioxa over time. These and other risks, uncertainties and factors related to Glaukos, and our business are described in detail under the caption “Risk Factors” and elsewhere in our Annual Report on Form 10-K for the year ended December 31, 2025, which was filed with the SEC on February 23, 2026. Our filings with the SEC are available in the Investor Section of our website at www.glaukos.com or at www.sec.gov. In addition, information about the risks and benefits of our products is available on our website at www.glaukos.com. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on the forward-looking statements in this press release, which speak only as of the date hereof. We do not undertake any obligation to update, amend or clarify these forward-looking statements whether as a result of new information, future events or otherwise, except as may be required under applicable securities law.

More News From Glaukos Corporation

Back to Newsroom

Key Takeaways Glaukos gains CMS J-code J2789 for Epioxa, effective July 1, 2026, boosting reimbursement clarity.GKOS expects improved market access, simplified billing and broader payer coverage over time.Epioxa offers a non-invasive, oxygen-enriched therapy designed to reduce pain and recovery time. Glaukos (GKOS - Free Report) announced that its innovative keratoconus treatment, Epioxa (Epioxa HD / Epioxa), was assigned a permanent HCPCS J-code — J2789 — by the U.S. Centers for Medicare and Medicaid Services (“CMS”).

The J-code becomes effective from July 1, 2026, and is expected to streamline how Epioxa is reported and reimbursed by U.S. payers over time.

Per management, the new product-specific J-code for Epioxa is an important step in improving market access, helping expand coverage for keratoconus patients. Once active, this new J-code should simplify reimbursement, strengthen the foundation of commercial launch and improve patient access over time.

Likely Trend of GKOS Stock Following the NewsFollowing the announcement, GKOS shares gained 0.4% at yesterday’s closing. In the year-to-date period, shares of the company have climbed 7.1% against the industry’s 11.6% decline. However, the S&P 500 has risen 1.9% during the same time frame.

In the long run, the J-code assignment for Epioxa positions Glaukos for a scalable growth trajectory. With streamlined reimbursement and improved payer clarity, the company can drive broader physician adoption and patient access. This milestone reduces administrative friction, enhances commercial execution and supports predictable revenue expansion. Coupled with Epioxa’s differentiated, non-invasive profile, Glaukos is well-positioned to strengthen its leadership in corneal therapies and deliver sustained growth in the keratoconus treatment landscape.

GKOS currently has a market capitalization of $7 billion.

Image Source: Zacks Investment Research

More on the NewsEpioxa itself represents a breakthrough in keratoconus treatment, providing an incision-free alternative to traditional corneal cross-linking by preserving the corneal epithelium. This oxygen-enriched, UV-activated topical therapy is designed to reduce pain, streamline the procedure and shorten recovery time, while delivering strong clinical results and value.

J-codes are used by U.S. healthcare providers to report treatments, and by government and commercial payers to simplify billing and reimbursement for physician-administered drugs like Epioxa. With the assignment of J2789, Glaukos is well-positioned to improve coverage consistency and reduce administrative friction for providers treating keratoconus.

Industry Prospects Favoring the MarketGoing by the data provided by Research Nester, the keratoconus treatment market is valued at $584.6 million in 2026 and is expected to witness a CAGR of 4.2% through 2035.

Factors like the rising prevalence of keratoconus, increased awareness of advanced non-invasive treatment, rising geriatric population and the continuous advancement of diagnostic technologies are boosting the market’s growth.

Other NewsIn January, Glaukos announced the FDA approval for the company’s NDA labeling supplement, permitting unlimited re-administration of iDose TR in eligible patients. This approval expands the product’s treatment flexibility and reinforces confidence in its long-term therapeutic profile.

GKOS’ Zacks Rank & Stocks to ConsiderCurrently, GKOS has a Zacks Rank #4 (Sell).

Some better-ranked stocks from the broader medical space are Pacific Biosciences of California (PACB - Free Report) , Phibro Animal Health (PAHC - Free Report) and GE HealthCare Technologies (GEHC - Free Report) .

Pacific Biosciences of California, currently sporting a Zacks Rank #1 (Strong Buy), reported a fourth-quarter 2025 adjusted loss of 12 cents per share, 36.8% narrower than the Zacks Consensus Estimate. Revenues of $44.6 million beat the Zacks Consensus Estimate by 9.4%. You can see the complete list of today’s Zacks #1 Rankstocks here.

PACB has an estimated earnings recession rate of 1.9% compared with the industry’s 12.9% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 27.7%.

Phibro Animal Health, currently carrying a Zacks Rank #2 (Buy), reported second-quarter fiscal 2026 adjusted earnings per share (EPS) of 87 cents, which surpassed the Zacks Consensus Estimate by 27.1%. Revenues of $373.9 million beat the Zacks Consensus Estimate by 4.7%.

PAHC has an estimated long-term earnings growth rate of 21.5% compared with the industry’s 12.1% rise. The company’s earnings beat estimates in the trailing four quarters, the average surprise being 20.1%.

GE HealthCare Technologies, currently carrying a Zacks Rank #2, reported fourth-quarter 2025 adjusted EPS of $1.44, which surpassed the Zacks Consensus Estimate by 0.7%. Revenues of $5.7 billion beat the Zacks Consensus Estimate by 1.9%.

GEHC has an estimated long-term earnings growth rate of 9.1% compared with the industry’s 12.1% rise. The company beat earnings estimates in the trailing four quarters, the average surprise being 7.5%.

Glaukos (GKOS) came out with a quarterly loss of $0.18 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.22 per share a year ago.

Glaukos Corporation (GKOS) Q1 2026 Earnings Call Transcript

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Glaukos Corporation (NYSE: GKOS), an ophthalmic pharmaceutical and medical technology company focused on novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases, today announced that its management is scheduled to participate in the following upcoming investor conferences: Stifel Virtual Ophthalmology Forum on Tuesday, May 26, 2026, at 1:30 p.m. ET William Blair 46th Annual Growth Stock Conference on Tuesday, June 2, 2026, at.

When investors think of artificial intelligence (AI) stocks, Arista Networks (ANET +3.80%) isn't a top-of-mind name. But understandably so. With a much smaller business compared to Nividia's and Alphabet's, it just doesn't garner much attention. The stock hasn't been performing particularly well since October anyway, giving the market even less reason to take notice.

Nevertheless, this under-the-radar AI stock is a buy before its next earnings report, due in early August, because of what happened -- or more specifically, what didn't happen -- following the release of its first-quarter results in early May.

Investors decide the glass is half-empty No, the stock didn't experience a post-earnings surge early last month. Quite the opposite, actually. It fell (sharply) despite topping its first-quarter earnings and revenue estimates in addition to raising its Q2 2026 revenue guidance. As it turns out, Arista didn't raise its guidance as much as investors and analysts were tacitly expecting it to. Those lofty expectations were already priced in, it seems.

Today's Change

(

3.80

%) $

5.94

Current Price

$

162.34

That's a mistake that isn't apt to happen again.

But first things first. What's Arista Networks, and what makes it an artificial intelligence stock?

It's mostly a networking outfit. Routers, cables, and the specialty software meant to get the maximum performance out of its hardware are all in its wheelhouse. As it turns out, this is artificial intelligence's biggest data bottleneck right now. Offering real solutions to this problem is why Arista's first-quarter revenue grew to the tune of 35% year over year, extending and accelerating last year's growth trend.

Image source: Getty Images.

The company's management team committed the cardinal sin no technology name can afford to commit at this time, but they candidly acknowledged that demand for Arista's technology is outpacing the supply of the components and materials it needs to manufacture its solutions, so much so that it's ultimately crimping profit margins as a result. Specifically, Arista is now looking for full-year operating margins of only 46%, down slightly from last year's average of just above 48%.

Investors simply panicked in response to the unexpected news.

All the bad news is already priced in In retrospect, though, the market arguably overreacted.

Although this year's profit margins are likely to come in slightly lower than last year's and the stock was richly priced for perfection, the top-line growth of 29% that analysts expect this year is still very impressive, as is the 22% earnings growth the analyst community is modeling for 2026. Next year's projected sales and profit growth are solid as well, in line with this year's anticipated improvements.

More importantly to interested investors, the shock stemming from the company's disappointing guidance delivered with its Q1 results has seemingly run its course. It's unlikely to take the same toll again the next time around in early August, when we'll be getting Q2's numbers; the bad news is already built in, and then some.

At least analysts seem to think so. Despite all the recent (mostly bearish) drama, the vast majority of analysts still rate ANET stock as a strong buy, with a 12-month price target of $188.42 that's nearly 20% above the stock's present price (at the time of this writing). That's not a bad way to start a new trade.

The stock may have been treated harshly based on the company's fundamentals alone, but the drop makes more sense in the context of the broader AI landscape.

Arista Networks, Inc. (ANET) Presents at 46th Annual William Blair Growth Stock Conference Transcript

Arista Networks, Inc. (ANET) Presents at Bank of America 2026 Global Technology Conference Transcript

Arista Networks Inc (NYSE:ANET) experienced a significant Power Inflow alert, a key bullish indicator that is closely tracked by traders who value order flow analytics, specifically institutional and retail order flow data.

Arista Networks remains a top pick for hardware/capex exposure, supported by robust AI-driven demand and market leadership. ANET projects its total addressable market to reach $105 billion by 2029, up from $60 billion by 2027, driven by AI networking needs. Despite supply constraints, ANET sustains ~30% revenue growth and expects a 25% CAGR through 2028, with 60%+ gross margins reflecting pricing power.

Arista Networks proves their AI beneficiary status through the twice-raised FY2026 guidance, supported by the growing purchase commitments and the expanding interconnect TAM. This is on top of the expanding hyperscaler/neocloud monetization trends, with further growth expected through the new scale-up/out/across Ethernet offerings and the upcoming CPU renaissance. The recent correction has triggered ANET's cheaper P/E of 45.74x and 3Y PEG of 2.06x, with the macro/AI funding pessimism triggering a dip buying opportunity.

SANTA CLARA, Calif.--(BUSINESS WIRE)--Arista Networks (NYSE: ANET), a leader in modern AI fabric networking, today announced the Arista 7060XE7 Series, a new portfolio of 1.6T networking platforms designed specifically as the foundation for rack-scale AI infrastructure. As AI workloads scale from thousands to hundreds of thousands of XPUs, the network has evolved from a standalone layer into a critical backplane for a tightly-integrated AI supersystem. The 7060XE7 Series represents Arista's tra.

ANET's debt-free balance sheet, rising cash reserves and surging operating cash flow highlight strong liquidity as AI and cloud demand fuel growth.

ANET rolls out 7060XE7 Series Ethernet platforms, delivering 1.6 Tbps per port and up to 100 Tbps switching capacity to meet surging AI infrastructure demands.

Reports 15% YoY ARR Growth and Solid Free Cash Flow Performance Delivers Outperformance Across All Guided Metrics SAN JOSE, Calif., May 27, 2026 (GLOBE NEWSWIRE) -- Nutanix, Inc. (NASDAQ: NTNX ), a leader in hybrid multicloud computing, today announced financial results for its third quarter ended April 30, 2026.

While the top- and bottom-line numbers for Nutanix (NTNX) give a sense of how the business performed in the quarter ended April 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Nutanix (NASDAQ:NTNX) reported upbeat earnings for the third quarter on Wednesday.